Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1993-03-26
1998-10-20
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514 75, 514114, 514665, A01N 5710, A01N 5700, A61K 3166, A61K 3113
Patent
active
058246649
ABSTRACT:
Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.
REFERENCES:
patent: 4970212 (1990-11-01), Nowicky
patent: 5218088 (1993-06-01), Gorenstein et al.
Kalebic et al, J. Cell. Biochem., Supp 16E. p. 81 (1992).
Agostini et al., "Release of granulocyte-macrophage colony-stimulating factor by alveolar macrophages in the lung of HIV-1-infected patients", The Journal of Immunology 149(10): 3379-3385 (1992).
Baker and Wood, "Cellular antioxidant status and human immunodeficiency virus replication", Nutrition Reviews 50(1): 15-18 (1992).
Droge et al., "HIV-induced cysteine deficiency and T-cell dysfunction--a rationale for treatment with N-acetylcysteine", Immunology Today 13(6): 211-214 (1992).
Grdina et al., "Protection against AZT-induced mutagenesis at the HGPRT locus in a human cell line by WR-151326", Int. J. Radiation Oncology Biol. Phys. 22: 813-815 (1992).
Ohnishi et al., "In vitro study on the antioxidant activities of amifostine (WR-2721)", Proceedings of the American Association for Cancer Research 33: Abstract 2503, p. 419 (1992).
Roederer et al., "N-acetylcysteine: A new approach to anti-HIV therapy", Aids Research and Human Retroviruses 8(2): 209-217 (1992).
Staal et al., "Glutathione deficiency and human immunodeficiency virus infection", The Lancet 339: 909-912 (1992).
Staal et al., "Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals", Aids Research and Human Retroviruses 8(2): 305-311 (1992).
Eck et al., "Metabolic disorder as early consequence of simian immunodeficiency virus infection in rhesus macaques", The Lancet 338: 346-347 (1991).
Grdina et al., "Protection by WR-151327 against late-effect damage from fission-spectrum neutrons", Radiation Research 128: S124-S127 (1991).
Green and Schein, "WR-151327: An orally active aminothiol chemoprotector for platinum and AZT toxicities in mice", Proceedings of the American Association for Cancer Research 32: Abstract 1906, p. 321 (1991).
Harakeh and Jariwalla, "Comparative study of the anti-HIV activities of ascorbate and thiol-containing reducing agents in chronically HIV-infected cells", Am. J. Clin. Nutr. 54: 1231S-1235S (1991).
Kalebic et al., "Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine", Proc. Natl. Acad. Sci. USA 88: 986-990 (1991).
Rieckmann et al., "Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1", The Journal of Experimental Medicine 173: 1-5 (1991).
Breen et al., "Infection with HIV is associated with elevated IL-6 levels and production", The Journal of Immunology 144(2): 480-484 (1990).
Fauci, "Cytokine regulation of HIV expression", Lymphokine Research 9(4): 527-531 (1990).
Harakeh et al., "Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells", Proc. Natl. Acad. Sci. USA 87: 7245-7249 (1990).
Kubota et al., "2,3 Dimercapto-1-Propanol inhibits HIV-1 tat activity, viral production, and infectivity in vitro", Aids Research and Human Retroviruses 6(7): 919-927 (1990).
Odeh, "The role of tumour necrosis factor-.alpha. in acquired immunodeficiency syndrome", Journal of Internal Medicine 228: 549-556 (1990).
Poli et al., "Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor .alpha. by transcriptional and post-transcriptional mechanisms", The Journal of Experimental Medicine 172: 151-158 (1990).
Staal et al., "Intracellular thiols regulate activation of nuclear factor .kappa.B and transcription of human immunodeficiency virus", Proc. Natl. Acad. Sci. USA 87: 9943-9947 (1990).
Buhl et al., "Systemic glutathione deficiency in symptom-free HIV-seropositive individuals", The Lancet II: 1294-1298 (1989).
Clouse et al., "Viral antigen stimulation of the production of human monokines capable of regulating HIV1 expression", The Journal of Immunology 143(2): 470-475 (1989).
Eck et al., "Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients", Biological Chemistry Hoppe-Seyler 370: 101-108 (1989).
Kharazmi et al., "Interleukin 6 primes human neutrophil and monocyte oxidative burst response", Immunology Letters 21: 177-184 (1989).
Meister, "On the biochemistry of glutathione", Glutathione Centennial, Academic Press, Inc., pp. 3-21 (1989).
Merrill et al., "Interleukin-1 and tumor necrosis factor .alpha. can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor", Jounal of Virology 63(10): 4404-4408 (1989).
Nakajima et al., "Induction of IL-6 (B cell stimulatory factor-2/IFN-.beta..sub.2) production by HIV", The Journal of Immunology 142(2): 531-536 (1989).
Poli et al., "Interferon-.alpha. but not AZT suppresses HIV expression in chronically infected cell lines", Science 244: 575-577 (1989).
Roux-Lombard et al., "Purified blood monocytes from HIV 1-infected patients produce high levels of TNF.alpha. and IL-1", Clinical Immunology and Immunopathology 50: 374-384 (1989).
Stanley et al., "Induction of expression of human immunodeficiency virus in a chronically infected promonocytic cell line by ultraviolet irradiation", Aids Research and Human Retroviruses 5(4): 375-384 (1989).
Folks et al., "Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate", The Journal of Immunology 140(4): 1117-1122 (1988).
Lahdevirta et al., "Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome", The American Journal of Medicine 85: 289-291 (1988).
Reddy et al., "Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations", Journal of Acquired Immune Deficiency Syndromes 1: 436-440 (1988).
Willey et al., "In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity", Journal of Virology 62(1): 139-147 (1988).
Folks et al., "Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line", Science 238: 800-802 (1987).
Mitsuya and Broder, "Strategies for antiviral therapy in AIDS", Nature 325: 773-778 (1987).
Steel et al., "Protection of mice against fission neutron irradiation by WR-2721 or WR-151327", Radiation Research 109: 469-478 (1987).
Klebanoff et al., "Stimulation of neutrophils by tumor necrosis factor", The Journal of Immunology 136(11): 4220-4225 (1986).
Meister et al., "Intracellular cysteine and glutathione delivery systems", Journal of the American College of Nutrition 5: 137-151 (1986).
Sigdestad et al., "A comparison of radioprotection from three neutron sources and .sub.60 Co by WR-2721 and WR-151327", Radiation Research 106: 224-233 (1986).
Cathcart et al., "Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS)", Medical Hypotheses 14: 423-433 (1984).
Gorman et al., "Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells", Molecular and Cellular Biology 2(9): 1044-1051 (1982).
Yuhas, "Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid", Cancer Research 40: 1519-1524 (1980).
DeChatelet et al., "Effect of phorbol myristate acetate on the oxidative metabolism of human polymorphonuclear leukocytes", Blood 47(4): 545-554 (1976).
Kalebic Thea
Schein Philip S.
Lankford , Jr. Leon B.
National Institutes of Health, The National Cancer Institute
Prats Francisco C.
U.S. Bioscience, Inc.
LandOfFree
Suppression of HIV expression by organic thiophosphate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of HIV expression by organic thiophosphate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of HIV expression by organic thiophosphate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244466